Evidence map›Paper›PMID 38814086›Full record

ArticleJournal of medicinal chemistry2024

Systematic Structure-Activity Relationship Study of Nalfurafine Analogues toward Development of Potentially Nonaddictive Pain Management Treatments.

Celsey M St Onge, Piyusha P Pagare, Yi Zheng, Michelle Arriaga, David L Stevens, Rolando E Mendez, Justin L Poklis, Matthew S Halquist, Dana E Selley, William L Dewey and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Celsey M St OngeDepartment of Medicinal Chemistry, Virginia Commonwealth University, 800 E. Leigh Street, Richmond, Virginia 23219, United States.ORCID 0000-0002-9845-7118
Piyusha P PagareDepartment of Medicinal Chemistry, Virginia Commonwealth University, 800 E. Leigh Street, Richmond, Virginia 23219, United States.ORCID 0000-0002-4848-2673
Yi ZhengDepartment of Medicinal Chemistry, Virginia Commonwealth University, 800 E. Leigh Street, Richmond, Virginia 23219, United States.
Michelle ArriagaDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 North 12th Street, Richmond, Virginia 23298, United States.
David L StevensDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 North 12th Street, Richmond, Virginia 23298, United States.
Rolando E MendezDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 North 12th Street, Richmond, Virginia 23298, United States.
Justin L PoklisDepartment of Pharmaceutics, Virginia Commonwealth University, 410 North 12th Street, Richmond, Virginia 23298, United States.
Matthew S HalquistDepartment of Pharmaceutics, Virginia Commonwealth University, 410 North 12th Street, Richmond, Virginia 23298, United States.
Dana E SelleyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 North 12th Street, Richmond, Virginia 23298, United States.
William L DeweyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 North 12th Street, Richmond, Virginia 23298, United States.
Matthew L BanksDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 North 12th Street, Richmond, Virginia 23298, United States.ORCID 0000-0003-4949-5246
Yan ZhangDepartment of Medicinal Chemistry, Virginia Commonwealth University, 800 E. Leigh Street, Richmond, Virginia 23219, United States.ORCID 0000-0001-8934-7016

Funding

VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ARON H LICHTMAN · 2014 to 2026
$13.8M
Mu Opioid Receptor Modulator Development to Treat Opioid Use DisorderUH3DA050311 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ZHANG, YAN · 2023 to 2025
$4.3M
Development of Specific Mu Opioid Receptor Antagonists to Reverse the Acute and Chronic Toxicity of FentanylsUG3DA054785 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ZHANG, YAN · 2022 to 2022
$2.8M
Development of a Potential Treatment for Polysubstance Use DisordersF31DA054796 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ST. ONGE, CELSEY MACKENNA · 2021 to 2022
$80k
NIDA NIH HHS F31 DA054796NIDA NIH HHS P30 DA033934NIDA NIH HHS UG3 DA054785NIDA NIH HHS UH3 DA050311
6 · The paper itself

Abstract

Despite the availability of numerous pain medications, the current array of Food and Drug Administration-approved options falls short in adequately addressing pain states for numerous patients and consequently worsens the opioid crisis. Thus, it is imperative for basic research to develop novel and nonaddictive pain medications. Toward addressing this clinical goal, nalfurafine (NLF) was chosen as a lead and its structure-activity relationship (SAR) systematically studied through design, syntheses, and

Indexed as

MorphinansSpiro CompoundsAnalgesicsAnimalsHumansMaleMicePainPain ManagementReceptors, Opioid, kappaStructure-Activity RelationshipAnalgesicsMorphinansReceptors, Opioid, kappaSpiro CompoundsTRK 820

Identifiers

PMID38814086
PMCPMC11181328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.